Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane

D. Ribatti, C. Urbinati, B. Nico, M. Rusnati, L. Roncali, M. Presta

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Chorioallantoic membrane (CAM) and chorioallantoic fluid (CAF) of the chick embryo were studied for the presence of immunoreactive and biologically active basic fibroblast growth factor (bFGF) from Day 6 to Day 18 of incubation. An immunoreactive M(r) 16,000 bFGF-like molecule was detected both in CAM and in CAF. This molecule was identified as bPGF on the basis of its molecular weight, its affinity for heparin, and its capacity to induce plasminogen activator production in cultured endothelial GM 7373 cells. The levels of biologically active and immunoreactive bFGF vary in CAM and CAF during embryonic development, maximal concentrations being observed between Days 10 and 14 of incubation. At all time points investigated, absolute concentrations of bFGF were significantly higher in CAM (ranging from 25 to 183 ng/g of wet tissue) than in CAP (ranging from 0.2 to 4 ng/ml). In a parallel series of experiments performed at Day 8 and evaluated at Day 12 of chick embryo development, human recombinant bFGF and neutralizing anti-bFGF antibody were investigated for their capacity to affect the vasoproliferative processes of the CAM. The two molecules either were applied onto the surface of the CAM or were injected into the allantoic sac. When bFGF or anti-bPGP antibodies were absorbed on methylcellulose discs and applied on the top of the CAM, they exerted a strong angiogenic or anti-angiogenic effect, respectively. On the contrary, when bFGF or the corresponding neutralizing antibody was injected into the allantoic sec, no modifications of the vasoproliferative processes of the CAM were observed at either the macroscopic or the microscopic level. These results provide evidence indicating that endogenous bFGF has a rate-limiting role in the vascularization of the CAM during chick embryogenesis. bBGF located within the CAM, rather than that present in the CAP, appears to be involved in this developmental process.

Original languageEnglish
Pages (from-to)39-49
Number of pages11
JournalDevelopmental Biology
Volume170
Issue number1
DOIs
Publication statusPublished - 1995

Fingerprint

Chorioallantoic Membrane
Fibroblast Growth Factor 2
Chick Embryo
Embryonic Development
Fibroblast Growth Factor 6
Methylcellulose
Plasminogen Activators
Neutralizing Antibodies
Heparin
Anti-Idiotypic Antibodies
Molecular Weight

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Cell Biology

Cite this

Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane. / Ribatti, D.; Urbinati, C.; Nico, B.; Rusnati, M.; Roncali, L.; Presta, M.

In: Developmental Biology, Vol. 170, No. 1, 1995, p. 39-49.

Research output: Contribution to journalArticle

Ribatti, D. ; Urbinati, C. ; Nico, B. ; Rusnati, M. ; Roncali, L. ; Presta, M. / Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane. In: Developmental Biology. 1995 ; Vol. 170, No. 1. pp. 39-49.
@article{99319173f4a4450f8050f07d5a8d0b06,
title = "Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane",
abstract = "Chorioallantoic membrane (CAM) and chorioallantoic fluid (CAF) of the chick embryo were studied for the presence of immunoreactive and biologically active basic fibroblast growth factor (bFGF) from Day 6 to Day 18 of incubation. An immunoreactive M(r) 16,000 bFGF-like molecule was detected both in CAM and in CAF. This molecule was identified as bPGF on the basis of its molecular weight, its affinity for heparin, and its capacity to induce plasminogen activator production in cultured endothelial GM 7373 cells. The levels of biologically active and immunoreactive bFGF vary in CAM and CAF during embryonic development, maximal concentrations being observed between Days 10 and 14 of incubation. At all time points investigated, absolute concentrations of bFGF were significantly higher in CAM (ranging from 25 to 183 ng/g of wet tissue) than in CAP (ranging from 0.2 to 4 ng/ml). In a parallel series of experiments performed at Day 8 and evaluated at Day 12 of chick embryo development, human recombinant bFGF and neutralizing anti-bFGF antibody were investigated for their capacity to affect the vasoproliferative processes of the CAM. The two molecules either were applied onto the surface of the CAM or were injected into the allantoic sac. When bFGF or anti-bPGP antibodies were absorbed on methylcellulose discs and applied on the top of the CAM, they exerted a strong angiogenic or anti-angiogenic effect, respectively. On the contrary, when bFGF or the corresponding neutralizing antibody was injected into the allantoic sec, no modifications of the vasoproliferative processes of the CAM were observed at either the macroscopic or the microscopic level. These results provide evidence indicating that endogenous bFGF has a rate-limiting role in the vascularization of the CAM during chick embryogenesis. bBGF located within the CAM, rather than that present in the CAP, appears to be involved in this developmental process.",
author = "D. Ribatti and C. Urbinati and B. Nico and M. Rusnati and L. Roncali and M. Presta",
year = "1995",
doi = "10.1006/dbio.1995.1193",
language = "English",
volume = "170",
pages = "39--49",
journal = "Developmental Biology",
issn = "0012-1606",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane

AU - Ribatti, D.

AU - Urbinati, C.

AU - Nico, B.

AU - Rusnati, M.

AU - Roncali, L.

AU - Presta, M.

PY - 1995

Y1 - 1995

N2 - Chorioallantoic membrane (CAM) and chorioallantoic fluid (CAF) of the chick embryo were studied for the presence of immunoreactive and biologically active basic fibroblast growth factor (bFGF) from Day 6 to Day 18 of incubation. An immunoreactive M(r) 16,000 bFGF-like molecule was detected both in CAM and in CAF. This molecule was identified as bPGF on the basis of its molecular weight, its affinity for heparin, and its capacity to induce plasminogen activator production in cultured endothelial GM 7373 cells. The levels of biologically active and immunoreactive bFGF vary in CAM and CAF during embryonic development, maximal concentrations being observed between Days 10 and 14 of incubation. At all time points investigated, absolute concentrations of bFGF were significantly higher in CAM (ranging from 25 to 183 ng/g of wet tissue) than in CAP (ranging from 0.2 to 4 ng/ml). In a parallel series of experiments performed at Day 8 and evaluated at Day 12 of chick embryo development, human recombinant bFGF and neutralizing anti-bFGF antibody were investigated for their capacity to affect the vasoproliferative processes of the CAM. The two molecules either were applied onto the surface of the CAM or were injected into the allantoic sac. When bFGF or anti-bPGP antibodies were absorbed on methylcellulose discs and applied on the top of the CAM, they exerted a strong angiogenic or anti-angiogenic effect, respectively. On the contrary, when bFGF or the corresponding neutralizing antibody was injected into the allantoic sec, no modifications of the vasoproliferative processes of the CAM were observed at either the macroscopic or the microscopic level. These results provide evidence indicating that endogenous bFGF has a rate-limiting role in the vascularization of the CAM during chick embryogenesis. bBGF located within the CAM, rather than that present in the CAP, appears to be involved in this developmental process.

AB - Chorioallantoic membrane (CAM) and chorioallantoic fluid (CAF) of the chick embryo were studied for the presence of immunoreactive and biologically active basic fibroblast growth factor (bFGF) from Day 6 to Day 18 of incubation. An immunoreactive M(r) 16,000 bFGF-like molecule was detected both in CAM and in CAF. This molecule was identified as bPGF on the basis of its molecular weight, its affinity for heparin, and its capacity to induce plasminogen activator production in cultured endothelial GM 7373 cells. The levels of biologically active and immunoreactive bFGF vary in CAM and CAF during embryonic development, maximal concentrations being observed between Days 10 and 14 of incubation. At all time points investigated, absolute concentrations of bFGF were significantly higher in CAM (ranging from 25 to 183 ng/g of wet tissue) than in CAP (ranging from 0.2 to 4 ng/ml). In a parallel series of experiments performed at Day 8 and evaluated at Day 12 of chick embryo development, human recombinant bFGF and neutralizing anti-bFGF antibody were investigated for their capacity to affect the vasoproliferative processes of the CAM. The two molecules either were applied onto the surface of the CAM or were injected into the allantoic sac. When bFGF or anti-bPGP antibodies were absorbed on methylcellulose discs and applied on the top of the CAM, they exerted a strong angiogenic or anti-angiogenic effect, respectively. On the contrary, when bFGF or the corresponding neutralizing antibody was injected into the allantoic sec, no modifications of the vasoproliferative processes of the CAM were observed at either the macroscopic or the microscopic level. These results provide evidence indicating that endogenous bFGF has a rate-limiting role in the vascularization of the CAM during chick embryogenesis. bBGF located within the CAM, rather than that present in the CAP, appears to be involved in this developmental process.

UR - http://www.scopus.com/inward/record.url?scp=0029111677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029111677&partnerID=8YFLogxK

U2 - 10.1006/dbio.1995.1193

DO - 10.1006/dbio.1995.1193

M3 - Article

C2 - 7601314

AN - SCOPUS:0029111677

VL - 170

SP - 39

EP - 49

JO - Developmental Biology

JF - Developmental Biology

SN - 0012-1606

IS - 1

ER -